Anti–Aquaporin‐4 monoclonal antibody blocker therapy for neuromyelitis optica

Lukmanee Tradtrantip,Hua Zhang,S. Saadoun,P. Phuan,C. Lam,M. Papadopoulos,J. Bennett,A. Verkman
DOI: https://doi.org/10.1002/ana.22657
IF: 11.2
2012-03-01
Annals of Neurology
Abstract:Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system. Circulating autoantibodies (NMO‐immunoglobulin [Ig]G) against astrocyte water channel aquaporin‐4 (AQP4) cause complement‐ and cell‐mediated astrocyte damage with consequent neuroinflammation and demyelination. Current NMO therapies, which have limited efficacy, include immunosuppression and plasma exchange. The objective of this study was to develop a potential new NMO therapy based on blocking of pathogenic NMO‐IgG binding to its target, AQP4.
What problem does this paper attempt to address?